Utility of contrast-enhanced computed tomography in the evaluation of canine insulinoma location

Buishand, Floryne O.; Grosso, Federico R. Vilaplana; Kirpensteijn, Jolle; Nimwegen, S.A. van

doi:10.1080/01652176.2018.1481545

Cited by 25 publications

(57 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CT scan identi ed a pancreatic mass in 10/12 (83%) dogs in which it was performed, including three dogs where the mass was not evident on ultrasound. Although CT scan has been shown to identify 71.4% of primary insulinomas in dogs, contrast-enhanced CT has also been reported to inaccurately locate insulinomas in dogs, and intraoperative evaluation of the pancreas and potential metastatic lesions is felt to be superior for staging purposes [48,49].…”

Section: Discussionmentioning

confidence: 99%

WITHDRAWN: Management of canine insulinomas with toceranib phosphate: 30 cases (2009-2019)

Sheppard‐Olivares¹,

Bello²,

Johannes³

et al. 2020

Preprint

View full text Add to dashboard Cite

BACKGROUNDInsulinomas are the most common tumour of the endocrine pancreas in dogs. These are malignant tumours with a high metastatic rate and limited efficacious chemotherapeutic options available. Recent literature supports the use of the multi-receptor tyrosine kinase inhibitor sunitinib malate for treatment of metastatic insulinoma in people. Toceranib phosphate is a veterinary targeted therapy that may provide benefit in treatment of canine insulinomas. The primary objectives of this retrospective study were to describe the control of clinical signs, response to toceranib in the case of measurable disease, and outcomes of toceranib therapy for canine insulinoma. A secondary objective was to describe the adverse effects of toceranib in dogs with insulinoma.RESULTSA medical record search identified 30 dogs diagnosed with insulinoma and treated with toceranib at five university hospitals and eight veterinary specialty referral hospitals. A majority (66.7%) of dogs with measurable disease experienced either complete response (CR), partial response (PR), or stable disease (SD) for a minimum of 10 weeks with toceranib therapy. The overall median progression free interval (PFI) was 561 days (95% confidence interval: [246, 727 days]). The overall medial survival time (OST) was 656 days [310, 1045 days]. Larger dogs were at increased risk for disease progression (P = 0.0310) and death (P = 0.0064), with every 1 kg increase in body weight resulting in hazard ratios (HRs) of 1.045 [1.003, 1.084] and 1.05 [1.012, 1.090], respectively. In addition, time to disease progression was associated with use of therapies prior to toceranib (P = 0.0050) and type of veterinary practice (P = 0.0025). The most common adverse events with toceranib therapy were grade 1 or 2 gastrointestinal toxicities.CONCLUSIONSClinical benefit was reported in the majority of dogs diagnosed with insulinoma treated with toceranib, but randomized, prospective studies are needed to assess and quantify the effect of this therapy. The most commonly observed adverse events (AEs) were grade 1 or 2 gastrointestinal AEs.

show abstract

Section: Discussionmentioning

confidence: 99%

WITHDRAWN: Management of canine insulinomas with toceranib phosphate: 30 cases (2009-2019)

Sheppard‐Olivares¹,

Bello²,

Johannes³

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…In veterinary medicine, CT angiography, including dual-phase and triple-phase helical CT, is widely used in clinical and experimental fields [ 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 ]. In these contrast CT imaging protocols, the timing of the start of scanning was determined based on previously reported TACs [ 13 , 14 , 15 ].…”

Section: Discussionmentioning

confidence: 99%

“…The arterial phase and portal venous phase are generally scanned within 1 min of the injection of the contrast medium: arterial phase, 15–20 s, and the portal venous phase, 30–40 s after injection. The delayed phase occurs about 2 min after contrast medium injection [ 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 ]. Under the sedation protocol in our study, the AO-EA appeared approximately 30 s after contrast medium injection and the peak AO enhancement about 1 min after injection.…”

Section: Discussionmentioning

confidence: 99%

“…In veterinary medicine, multiphasic multi-detector computed tomography (CT) angiography, including triple-phase helical CT, is currently used as a diagnostic tool for vascular disorders, such as portosystemic shunts [ 1 ], arteriovenous fistulae [ 2 ], and various tumors [ 3 , 4 , 5 , 6 , 7 , 8 ]. This method is also commonly used for characterizing parenchymal disease, such as pancreatic disease [ 9 , 10 , 11 , 12 ]. For triple-phase helical CT, a single bolus injection of contrast medium enhances imaging during the phase of preferential arterial enhancement, followed by the portal venous phase, and the delayed phase [ 5 , 6 ].…”

Section: Introductionmentioning

confidence: 99%

“…CT imaging further requires that the animal be immobilized, with anesthesia or sedation used to achieve this [ 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 ]. However, agents used for anesthesia and sedation can influence the cardiovascular circulation.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Effects of Sedation by Intramuscular Administration of Medetomidine on Canine Abdominal Vascular System and Hepatic Parenchyma Imaging Using Enhancement Dynamic Computed Tomography

Kutara

Kanda

Maeta

et al. 2020

Veterinary Sciences

View full text Add to dashboard Cite

This prospective crossover study compared the effects of intramuscular administration of medetomidine for sedation on parameters of the abdominal vascular system, measured by enhancement computed tomography (CT), to those of propofol-induced sevoflurane maintenance anesthesia, as a control, in five clinically healthy adult male beagle dogs (11.4–12.8 kg). Each animal underwent both protocols at a 1-week interval. The enhancement (HU) and time to peak enhancement on CT were measured for the aorta (AO), caudal vena cava (CVC), portal vein (PV), and hepatic parenchyma (HP). The contrast effects in the AO, PV, and HP were significantly delayed under medetomidine sedation compared to the control anesthesia protocol. Particularly, the contrast effect in the PV and HP was significantly delayed under sedation, appearing approximately 1 min after contrast medium injection. This delay likely reflects the peripheral vasoconstrictive effect of medetomidine. We noted a generally early high contrast enhancement of the CVC under medetomidine sedation, likely contributed by the induced bradycardia. Therefore, findings obtained on contrast enhancement CT under medetomidine sedation may be different from those obtained under propofol-induced sevoflurane maintenance anesthesia. These differences are important to consider when using the findings to inform diagnosis.

show abstract

Alimentary Tract

Culp¹,

Cavanaugh²,

Calfee³

et al. 2022

Veterinary Surgical Oncology

View full text Add to dashboard Cite

Utility of contrast-enhanced computed tomography in the evaluation of canine insulinoma location

Abstract: It is suggested that triple-phase CECT-scans have superior outcome over single- or double-phase CECT-scans in pre-operative imaging of canine insulinomas.

Cited by 25 publications

References 30 publications

WITHDRAWN: Management of canine insulinomas with toceranib phosphate: 30 cases (2009-2019)

WITHDRAWN: Management of canine insulinomas with toceranib phosphate: 30 cases (2009-2019)

Effects of Sedation by Intramuscular Administration of Medetomidine on Canine Abdominal Vascular System and Hepatic Parenchyma Imaging Using Enhancement Dynamic Computed Tomography

Alimentary Tract

Contact Info

Product

Resources

About